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OBJECTIVES This study was designed to assess the effect of oral L-arginine on the development of
tolerance during continuous transdermal nitroglycerin (TD-GTN) therapy.
BACKGROUND Continuous TD-GTN therapy leads to complete tolerance within 24 to 48 h. The
mechanism(s) responsible for nitrate tolerance are unclear, but there is increasing evidence
that nitroglycerin (GTN) leads to superoxide anion production. The trigger for this is
unknown, but there is evidence that GTN alters nitric oxide synthase (NOS) function and
also leads to reduced L-arginine availability at its site of action with NOS.
METHODS Fourteen patients with stable angina pectoris and reproducible treadmill walking time (TWT)
until the onset of moderate angina were studied in a placebo-controlled, crossover study.
Transdermal GTN (0.4 mg/h) was applied daily for two periods of 5 to 10 days with the patch
left in place for 24 h each day. Capsules containing L-arginine (700 mg) or placebo were
administered four times daily during a period of TD-GTN therapy. Treadmill walking time
was determined before and 4 h after study capsules on day 1 before TD-GTN to assess the
effect of L-arginine on exercise performance. On the last day, TWT was determined at 0 h
(24 h after TD-GTN and 9 h after study capsule) and 4 h after TD-GTN reapplication and
study capsule. After a 5 to 10 day washout period, the study was repeated with the opposite
study capsule.
RESULTS Treadmill walking time until the onset of moderate angina was not influenced by the
short-term administration of L-arginine. During continuous TD-GTN, the administration
of L-arginine increased TWT 4 h and 24 h after patch application. This was significantly
greater than TWT during administration of placebo capsules (p  0.05).
CONCLUSIONS The administration of L-arginine modified or prevented the development of nitrate tolerance
during continuous TD-GTN therapy. (J Am Coll Cardiol 2002;39:1199–203) © 2002 by
the American College of Cardiology Foundation
The organic nitrates are effective in the management of
patients with angina pectoris and are considered by many to
be first-line therapy for this disorder (1). However, the fact
that tolerance develops rapidly during continuous therapy
with nitrates limits their usefulness (2,3). Intermittent
dosing, which provides a period of nitrate washout, has been
shown to provide antianginal effects for 12 to 14 h, but this
is inadequate in many patients (4,5). If it were possible to
prevent or modify tolerance, the organic nitrates would be a
much better treatment option.
The mechanism(s) responsible for nitrate tolerance are
not completely understood. Hypotheses to explain this
phenomenon include: decreased bioconversion of nitrate to
nitric oxide (NO) due to sulfhydryl group depletion (6);
neurohormonal activation with release of vasoactive agents
(7,8); plasma volume expansion resulting in increased pre-
load (9,10); decreased cyclic guanosine monophosphate
production secondary to downregulation of guanylyl cyclase
(11); increased breakdown of cyclic guanosine monophos-
phate due to increased phosphodiesterase activity (12); and
superoxide anion production resulting in NO depletion
(13). Attempts to prevent or reverse nitrate tolerance with
sulfhydryl donors, angiotensin-converting enzyme inhibitors,
angiotensin receptor blocking agents, hydralazine, diuretics
and antioxidants have produced either negative or inconsis-
tent results (1). As a result none of these interventions has
been adopted into widespread clinical use.
In vitro studies have demonstrated an increase in super-
oxide anion production by endothelial cells exposed to
glyceryl trinitrate (GTN) (14). The source of this abnormal
superoxide anion production remains controversial, al-
though both membrane-bound oxidases and nitric oxide
synthase (NOS) itself have been implicated (15–17). The
trigger of this increase in superoxide production in response
to therapy with GTN remains unclear, although there is
considerable evidence that depletion of arginine is involved
(14,17). It has been hypothesized that intracellular deple-
tion of L-arginine leads to an uncoupling of NOS because
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of decreased substrate availability (14,17). This uncoupling,
in turn, leads to an increase in the bioavailability of
superoxide anion. This hypothesis suggests that arginine
supplementation during sustained GTN therapy might
prevent the development of nitrate tolerance. Continuous
transdermal GTN (TD-GTN) induces tolerance within
24 h of application (2). The present study was designed to
test the hypothesis that the supplemental administration of
L-arginine during continuous TD-GTN therapy would
prevent or modify tolerance in patients with stable angina
pectoris.
METHODS
This was a single-center study in patients with stable angina
pectoris. The protocol was approved by the Ethics Com-
mittee of the Queen’s University Affiliated Hospitals, and
each patient provided informed, written consent.
To be eligible for this study, patients had to have
documented coronary artery disease confirmed by evidence
of a previous myocardial infarction, significant coronary
angiography abnormalities, a myocardial perfusion scan
showing reversible perfusion defects or a positive dobut-
amine or stress echocardiographic study. On initial assess-
ment, patients had to develop moderate angina (P2) during
treadmill exercise testing between 2 and 8 min using the
standard Bruce protocol. The end point (P2) was defined as
the point at which patients would normally stop activity and
possibly take sublingual GTN for relief of pain. The
treadmill exercise time to P2 had to be reproducible with
two consecutive exercise tests carried out on different days
being within 15% of one another.
Exclusion criteria included myocardial infarction, unsta-
ble angina, a revascularization procedure within two
months, congestive heart failure, abnormal renal or liver
function tests, hemoglobin below 10 gm/l, systolic blood
pressure (BP) below 100 mm Hg or greater than 170 mm
Hg, or the use of digoxin, angiotensin-converting enzyme
inhibitors, angiotensin receptor blocking agents, amlodip-
ine, carvedilol or vitamin C or E. During the study, patients
were permitted to take beta adrenoreceptor blocking agents
and calcium channel antagonists (other than amlodipine).
The dose was kept constant throughout the study period,
and on study days these medications were taken after the
final exercise test. No long-acting nitrates were permitted,
but patients could use sublingual GTN to treat episodes of
angina. Patients were asked to avoid using sublingual GTN
for 2 h before any exercise test. If it was necessary for the
patient to take this medication, exercise testing was sched-
uled for another day.
This was a randomized, double-blind, placebo-controlled,
crossover study comparing the effects of L-arginine capsules
given four times daily and matching placebo during contin-
uous TD-GTN application. After fulfilling the entry crite-
ria and having none of the exclusion criteria, the definitive
investigation was carried out. On the initial study day,
treadmill exercise testing was carried out in the fasting state
without taking any medications. The time to the develop-
ment of moderate angina (P2) was determined. After this,
the study capsule (either 700 mg L-arginine or placebo) was
taken. Three to four hours later, a second exercise test was
carried out to the same end point. Transdermal nitroglyc-
erin (0.4 mg/h) was then applied and left in place until the
following morning. For the next 5 to 10 days, the patients
removed the TD-GTN each morning and replaced it with
a new one. During this period, patients took the study
capsules four times daily, with the last capsule taken at
approximately 11 PM. On the final study day, the patients
returned to the laboratory with the previous TD-GTN
patch in place and without taking the morning study
capsule. Exercise testing was carried out to the defined end
point. A new TD-GTN patch was then applied, the study
capsule was taken, and exercise testing was carried out after
3 to 4 h.
After the first study phase, there was a washout period of
at least five days during which no study capsules, TD-GTN
patches or long-acting oral nitrates were employed. After
this washout period, the study was repeated in an identical
fashion with continuous TD- GTN and the alternate study
capsule administered.
The protocol design allowed us to determine whether
L-arginine alone had an effect on exercise performance and
whether the administration of L-arginine modified the
development of tolerance during continuous TD-GTN
therapy.
Statistical methods. The Wilk-Shapiro test was applied to
test all data at all time points for normality (SAS release
6.11, SAS Institute Inc., Cary, North Carolina). The
method of Hills and Armitage for analysis of a two-period
crossover trial design was used to determine whether there
was a treatment effect (L-arginine vs. placebo) on treadmill
walking times (TWTs), heart rate and systolic BP (18). The
same method was applied to examine the data for an effect
of L-arginine alone on TWT. The analyses examined the
data for the presence of an interaction between the two
treatment arms. Such an interaction may be observed if one
double-blind treatment period has significant effects on the
subsequent treatment period. The analyses also examined
for the presence of a period effect. A period effect is found
when the observed result appears to be dependent on the
order of treatment.
Abbreviations and Acronyms
BP  blood pressure
GTN  nitroglycerin
NO  nitric oxide
NOS  nitric oxide synthase
TD-GTN  transdermal nitroglycerin
TWT  treadmill walking time
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RESULTS
Fourteen patients who fulfilled the inclusion criteria and
had none of the exclusion criteria completed this investiga-
tion. On the first study day of each of the two treatment
phases (Table 1, Fig. 1 ), there was no difference in exercise
duration between hour 0 and hour 4, when patients were
given either placebo or L-arginine capsules. On the final
study day of each treatment period, the 0-h test was carried
out with the previous TD-GTN in place (i.e., 24 h after
application) and before the morning capsule (i.e., 9 to 10 h
after the previous evening’s dose). The data at 4 h represent
TWT 4 h after TD-GTN reapplication and administration
of the study capsule. In comparison with placebo capsules,
L-arginine significantly prolonged TWT to moderate an-
gina at 4 h and 24 h after TD-GTN application (Table 1,
Fig. 1). This indicates the prevention of nitrate tolerance
during L-arginine administration. There were no significant
differences in the heart rate or systolic BP at rest or during
exercise during the two phases of the investigation.
DISCUSSION
The organic nitrates remain important agents in the man-
agement of patients with angina pectoris. There is, however,
a major drawback with nitrate therapy: it provides incom-
plete protection because it is not possible to provide anti-
anginal and anti-ischemic effects throughout 24 h each day,
owing to the rapid development of tolerance (2,3). Dosing
strategies that provide a period of washout have docu-
mented that antianginal and anti-ischemic effects can be
documented for 12 h with TD-GTN (4,19) and for 12 to
14 h with oral isosorbide-5-mononitrate given either as a
controlled release preparation (20) or as eccentric dosing
with immediate release isosorbide-5-mononitrate (21,22).
The intermittent regimen with nitrates may result in re-
bound ischemia during the nitrate-free period. This has
been shown in studies with TD-GTN (4,23,24) but has not
been studied carefully with oral nitrate preparations.
The present study documents that L-arginine alone does
not improve exercise duration in patients with stable angina.
However, during continuous TD-GTN therapy, a regimen
that has been shown to induce tolerance within 24 h,
L-arginine improves exercise performance for up to 24 h.
This is in contrast with the complete tolerance seen during
continuous TD-GTN alone, when placebo capsules were
taken. Of note, this is the first reported regimen in which
significant antianginal effects were observed throughout the
24 h during continuous nitrate therapy. The results of this
Table 1. Treadmill Exercise Time to Moderate Angina (s)
Placebo LA
Day 1
0 h 289  83 287  81
4 h 307  106 303  97
PL  TD-GTN LA  TD-GTN
Days 5–10
0 (24 h) 304  110* 274  93
4 h 314  95† 287  96
Data are mean  SD. *p  0.05 (confidence interval: 2.7, 51.5); †p  0.05
(confidence interval: 1.3, 49.4).
LA  L-arginine; PL  placebo; TD-GTN  transdermal nitroglycerin patches.
Figure 1. Treadmill walking time to the onset of moderate angina (P2) during the two treatment periods. Open bars indicate treatment with transdermal
nitroglycerin and placebo. Hatched bars indicate treatment with transdermal nitroglycerin and L-arginine. *p  0.05 versus baseline (0 hour, day 1).
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investigation support observations from two studies with
L-arginine. One of these documented improved exercise
tolerance in patients with angina treated with nitrates (25),
and the other showed reversal of tolerance that developed
during intravenous GTN therapy (26).
Mechanisms of tolerance. Recent advances have been
made in our understanding of the etiology of nitrate
tolerance. Important observations demonstrated that vessels
exposed to nitrates, particularly GTN, developed specific
biochemical abnormalities, including increased superoxide
anion generation and endothelin-I content (13,27). In-
creased production of superoxide anion was found to be
dependent on the presence of the endothelium, and animal
studies revealed that tolerance to GTN was, in large part, an
endothelium-dependent process (13,15). These observa-
tions have led to clinical investigations demonstrating that
continuous, and intermittent, GTN therapy are both asso-
ciated with the development of endothelial dysfunction in
the coronary and peripheral circulation (28–30). Clinical
investigations have also been carried out suggesting that the
development of tolerance can be prevented by concurrent
therapy with antioxidant vitamins (31,32).
Free radical generation and tolerance. This body of work
has led to the free radical hypothesis of nitrate tolerance, a
hypothesis that suggests that tolerance is associated with
increased vascular superoxide anion production and de-
creased NO bioavailability. Important questions remain
concerning the exact mechanism triggering increased super-
oxide production by the endothelium. The source of nitrate-
induced superoxide anion production was originally re-
ported to be membrane bound (NADH and NADPH)
oxidases, a process that was found to be promoted by
angiotensin II (15,33,34). More recently, endothelial NO
synthase (NOS) has also been reported as a source of
increased superoxide anion production in response to GTN
treatment (16,17). Evidence derived from animal experi-
ments suggests that GTN therapy causes an uncoupling of
NOS, such that the enzyme preferentially utilizes molecular
oxygen with the resultant production of superoxide anion.
The mechanism of this triggering remains unclear and may
be multifactorial. Importantly, it has been demonstrated
that the NO donor GTN activates NOS and, thus, increases
L-arginine requirements (14). This increase in L-arginine
demand leads to relative L-arginine depletion, resulting in
the uncoupling of NOS and increased superoxide anion
generation (14,17). A number of lines of evidence suggest
that changes in L-arginine transport mechanisms during
therapy with GTN may be important. In vitro studies have
demonstrated that NO donors reduce the transport of
L-arginine, leading to depletion of this substrate (14,35). It
is now recognized that the arginine transporter and NOS
are co-localized within caveolae of the endothelial cell and
that changes in arginine concentration may not be uniform
throughout the endothelial cell (17,36). These observations
have led to the arginine-depletion hypothesis of nitrate
tolerance. In this case, therapy with nitrates leads to
L-arginine depletion within caveoli of endothelial cells with
resultant uncoupling of NOS and increased superoxide
anion production. In vitro studies have demonstrated that
L-arginine supplementation prevents the uncoupling of
NOS during nitrate exposure and modifies the development
of tolerance (35). Of note, there is some experimental
evidence to suggest that L-arginine has antioxidant effects
as a scavenger for superoxide anion (37). This characteristic
might also play a role in modifying redox responses to GTN
therapy.
It is important to point out that the majority of experi-
mental data concerning increased free radical production
during nitrate exposure have involved GTN. Whether
increased free radial production occurs with other organic
nitrates remains unclear. Reports in animal models and in
humans have suggested that pentaerythrityl tetranitrate may
not lead to increased free-radical formation (38). As yet,
there are no clear data concerning the effect of isosorbide
dinitrate and the isosorbide mononitrates on the generation
of oxygen-free radicals.
If NO donated by the organic nitrates oxidatively injures
the arginine transport system, why does endogenous NO
not lead to such abnormalities? It has been demonstrated
that NOS agonists, such as bradykinin and acetylcholine,
increase L-arginine transport instead of leading to the
inhibition seen with GTN. One explanation for the lack of
inhibition of the transport system with NOS agonists could
be that the amount of NO produced upon NOS activation
is far less than the amount released by NO donors. Another
possible explanation for the lack of inhibition of L-arginine
transport with these agonists is that L-arginine is converted
to the intermediate 4-N(G)-hydroxyl-L-arginine before
formation of NO. L-hydroxyl arginine is an antioxidant and
an inhibitor of arginase (39,40), and this may provide
protection from oxidation by newly formed NO.
This is the first study demonstrating an intervention that
would provide beneficial effects of an organic nitrate on
exercise performance for up to 24 h. It is interesting to note
that an intervention designed to prevent abnormalities in
NOS function during GTN treatment may also be able to
prevent the development of tolerance. This has been sug-
gested by a recent observation by one of us who was
examining the impact of supplemental folate on both
endothelial function and vascular tolerance (41,42). The
observation that supplemental L-arginine is associated with
continued clinical effectiveness of TD-GTN supports the
L-arginine-depletion hypothesis as a significant factor in
the development of nitrate tolerance. The small number of
patients in this pilot study is a significant weakness. The
improvement in exercise performance 4 h and 24 h after
TD-GTN during continuous therapy, when patients were
receiving L-arginine, is of statistical significance, but the
confidence intervals are wide. The data suggest that
L-arginine supplementation modified the development of
tolerance to GTN, but it cannot be stated that this modi-
fication completely prevents tolerance. In order to make the
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latter statement, it would be necessary to compare the initial
responses to TD-GTN and placebo in a blinded fashion in
these patients. Unfortunately, placebo TD-GTN was not
available to us.
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